Renal Cancer - Results from #740

Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab + axitinib vs. ipilimumab + nivolumab. September 20, 2023

FDA Accepts for Priority Review Merck’s Supplemental New Drug Application for WELIREG® (belzutifan) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC) September 19, 2023

Complications after partial nephrectomy: robotics overcomes open surgery and laparoscopy: the PMSI French national database. September 19, 2023

Efficacy and safety of cabozantinib rechallenge in metastatic renal cell carcinoma: A retrospective multicentric study. September 19, 2023

Establishment of a new prognostic risk model of GNG7 pathway-related molecules in clear cell renal cell carcinoma based on immunomodulators. September 18, 2023

Socioeconomic determinants of racial disparities in survival outcomes among patients with renal cell carcinoma. September 18, 2023

Early kinetics of C-reactive protein as prognosticator for survival in a real-world cohort of patients with metastatic renal cell cancer under first-line therapy with immune checkpoint inhibitors. September 15, 2023

A comprehensive analysis of MYO6 as a promising biomarker for diagnosis, prognosis, and immunity in clear cell renal cell carcinoma. September 15, 2023

Contemporary patients have better perioperative outcomes following cytoreductive nephrectomy: a multi-institutional analysis of 1272 consecutive patients. September 14, 2023

The prognostic value of cancer stage-associated genes in clear cell renal cell carcinoma. September 14, 2023

Nephron Sparing Treatment (NEST) for Small Renal Masses: A Feasibility Cohort-embedded Randomised Controlled Trial Comparing Percutaneous Cryoablation and Robot-assisted Partial Nephrectomy. September 13, 2023

Advanced Non-Clear Cell Renal Cell Carcinoma Treatments and Survival: A Real-World Single-Centre Experience. September 13, 2023

Indications and Outcomes for Deferred Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Combination Therapy: Can Systemic Therapy be Withdrawn in Patients with No Evidence of Disease? September 12, 2023

Significance of timing of therapeutic line on effectiveness of nivolumab for metastatic renal cell carcinoma. September 12, 2023

Integrating bioinformatic analysis and detailed experiments reveal an EMT-related biomarker for clear cell renal cell carcinoma. September 11, 2023

ABCC2 brush-border expression predicts outcome in papillary renal cell carcinoma: a multi-institutional study of 254 cases. September 11, 2023

The Role of 99mTc-Sestamibi Single-photon Emission Computed Tomography/Computed Tomography in the Diagnostic Pathway for Renal Masses: A Systematic Review and Meta-analysis. September 8, 2023

Clinical application of superselective transarterial embolization of renal tumors in zero ischaemia robotic-assisted laparoscopic partial nephrectomy. September 8, 2023

Real-time Estimation of Nephron Activity with a Linear Measurement System (RENAL-MS) Predicts Postoperative eGFR. September 7, 2023

Kidney function and risk of Renal Cell Carcinoma. September 7, 2023

Page 38 of 456